MedTrace Logo

Home High-Flow Nasal Cannula vs. Noninvasive Ventilation for Stable Chronic Respiratory Failure

NCT06872801 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2025-03-12

No results posted yet for this study

Summary

The goal of this clinical trial is to compare the effects of home high-flow nasal cannula (HFNC) therapy and noninvasive ventilation (NIV) in patients with stable chronic hypercapnic respiratory failure. The main questions it aims to answer are:

* Does HFNC or NIV reduce blood carbon dioxide levels more effectively?
* How well do patients tolerate and adhere to each therapy?
* Are there differences in oxygen saturation, respiratory rate, and quality of life between the two treatments?

Participants Will:

* Use either HFNC (myAirvo2®) or NIV (Trilogy Evo®) every night for at least 4 hours over a 6-week period.
* Visit the hospital for checkups and arterial blood gas tests at the end of each 6-week period.
* Switch to the alternate device after six weeks as part of the crossover study design.
* Have their device usage recorded and analyzed.

Conditions

  • Stable Chronic Hypercapnic Respiratory Failure

Interventions

DEVICE

High-Flow Nasal Cannula

To compare the effects of NIV (Trilogy Evo®) and HFNC (myAirvo2®) in patients with chronic hypercapnic COPD.

DEVICE

Noninvasive Ventilation

to compare the effects of NIV (Trilogy Evo®) and HFNC (myAirvo2®) in patients with chronic hypercapnic COPD

Sponsors & Collaborators

  • Wonju Severance Christian Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-31
Primary Completion
2026-03-31
Completion
2026-06-30
FDA Device
Yes

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06872801 on ClinicalTrials.gov